MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients

MetaVia Inc.

DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).
Statistically significant improvements in CAP score (p=0.0308) and HbA1C (p=0.0179) vs placebo at week 16.
DA-1241 was very well tolerated; no drug-related serious adverse events reported across treatment groups.
Company plans end-of-Phase 2 meeting with FDA in first half of 2025; full data set awaited.
DA-1241 100mg + sitagliptin also showed significant FAST score reduction (p=0.0416).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.